Chief Scientific Officer & Chief Operating Officer Pad Chivukula sold 12,000 shares of Arcturus Therapeutics Holdings Inc (ARCT, Financial) on October 15, 2024, as reported in a recent SEC Filing. Following this transaction, the insider now owns 435,334 shares of the company.
Arcturus Therapeutics Holdings Inc is a biotechnology company focused on the discovery, development, and commercialization of RNA therapeutics for rare diseases and vaccines. The company utilizes proprietary technologies like LUNAR lipid-mediated delivery to develop novel RNA medicines, including RNA interference and messenger RNA therapeutics.
Over the past year, Pad Chivukula has sold a total of 69,114 shares and has not purchased any shares. The insider transaction history for the company shows no insider buys and 7 insider sells over the same timeframe.
On the day of the recent sale, shares of Arcturus Therapeutics Holdings Inc were trading at $20.76, giving the company a market cap of approximately $557.878 million.
According to the GF Value, the stock has a price-to-GF-Value ratio of 0.39, suggesting that it is a Possible Value Trap, Think Twice. The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted by a GuruFocus factor based on past returns and growth, and future business performance estimates from analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
